Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Idec and Alnylam to Collaborate on RNAi Therapeutics for PML

NEW YORK (GenomeWeb News) - Biogen Idec and Alnylam will jointly develop RNAi therapeutics to treat progressive multifocal leukoencephalopathy, the companies said today.
Biogen Idec will finance all research and development activities and Alnylam will receive an upfront payment of $5 million.
Alnylam will also receive more than $51 million in milestone payments, royalties, and utilization fees if the collaboration successfully develops any therapeutic products.
Alnylam and Biogen Idec will initially investigate the potential of using RNAi technology to treat infections caused by the JC virus, which results in PML.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.